RMD stock forecast, quote, news & analysis

Key Takeaways

• ResMed shares traded near $195 in late July 2026, down roughly 2.5% over the trailing 30-day period, reflecting broader healthcare sector weakness and ongoing investor debate around GLP-1 drug impacts.
• The company announced a definitive agreement to sell its MatrixCare business for $490 million in cash, sharpening its focus on high-growth sleep health, breathing health, and connected home-based care.
• ResMed completed the $340 million acquisition of Noctrix Health in June, expanding into the restless legs syndrome market with an FDA De Novo-classified device.
• Analyst consensus remains a Moderate Buy with an average price target around $253, implying significant upside from current levels, as the stock trades at roughly 16 times forward earnings — its cheapest valuation in over a decade.
• Fourth-quarter and full-year fiscal 2026 results are scheduled for August 6, 2026, with consensus estimates pointing to approximately $1.46 billion in quarterly revenue and EPS of $2.90.
• Institutional interest remains steady, with several funds increasing positions during the first quarter of 2026 and overall institutional ownership standing at approximately 55%.

Current Market Snapshot

ResMed Inc. shares have pulled back noticeably from their 52-week high of $293.81, closing at $195.27 on July 24, 2026. The stock has faced headwinds tied to the broader healthcare sector sell-off, which was exacerbated by renewed U.S. tariff announcements affecting multiple trading partners. Concerns about GLP-1 weight-loss drugs potentially shrinking the addressable sleep apnea market over the long term have also weighed on investor sentiment, even as ResMed's own claims data consistently shows that patients using both GLP-1 therapies and CPAP demonstrate higher adherence and resupply rates. The stock's 200-day simple moving average sits at approximately $227, underscoring the extent of the recent de-rating despite the company delivering double-digit revenue growth and expanding gross margins.

ResMed (RMD) Business Overview and Competitive Position

ResMed is a global medical device and digital health company headquartered in San Diego, California, with operations spanning more than 140 countries. Founded in 1989, the company develops, manufactures, and distributes cloud-connected devices and software for the treatment and management of sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its core product portfolio includes continuous positive airway pressure (CPAP) and bilevel devices, masks, and related accessories under the AirSense 11 and AirTouch platforms. The company operates in two segments: Sleep and Breathing Health, which generates the majority of revenue, and Residential Care Software, which includes the Brightree and MEDIFOX DAN platforms. With a market capitalization of roughly $29 billion and a net cash position approaching $1 billion, ResMed maintains a formidable competitive moat built on clinical efficacy, a vast installed base, and an expanding AI-powered digital health ecosystem.

Recent Developments Driving RMD

The most consequential development in recent weeks was the July 7 announcement that ResMed will sell its MatrixCare business to private equity firm Frazier Healthcare Partners for $490 million in an all-cash transaction. MatrixCare, originally acquired in 2018 for $750 million, provides cloud-based electronic health record and care management software for skilled nursing, senior living, and home health providers. Based on preliminary fiscal 2026 results, the unit generated approximately $220 million in revenue and $55 million in adjusted operating profit. ResMed intends to use the net proceeds for an accelerated share repurchase program and general corporate purposes. William Blair analysts noted that while the deal will likely be somewhat dilutive to earnings per share in the near term, selling an underperforming asset addresses investor concerns about growth durability. The firm maintained its Outperform rating.

On the M&A front, ResMed completed its $340 million acquisition of Noctrix Health in early June, adding the Nidra Tonic Motor Activation Therapy device for moderate-to-severe restless legs syndrome (RLS) to its portfolio. RLS affects approximately 7% of adults globally, and the condition overlaps meaningfully with ResMed's core sleep apnea patient population. Management has indicated the Noctrix business carries higher revenue growth rates and gross margins than ResMed's corporate average, though it is expected to reduce non-GAAP EPS by approximately $0.20 in fiscal 2027 as the company invests in commercialization.

ResMed also announced a CFO transition, with long-time finance chief Brett Sandercock retiring and Aaron Bloomer, formerly CFO of Exact Sciences, stepping into the role. On the analyst front, ratings remain broadly constructive: RBC Capital holds an Outperform rating (price target $276), JPMorgan initiated coverage with Overweight, while Morgan Stanley and Wells Fargo maintain Equal Weight ratings. The consensus price target of approximately $253.50 suggests substantial upside.

Trending AI Robots

Investors seeking systematic, data-driven approaches to stock selection may find value in exploring Tickeron's Trending AI Robots page. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across equities, ETFs, and other instruments. The Trending AI Robots section curates only the top-performing and most relevant bots at any given time, making it easier for users to identify strategies with strong recent track records. Bots vary by trading style, holding period, and risk profile — ranging from short-term swing-trading algorithms to longer-term trend-following models — and each displays transparent performance metrics. Whether monitoring healthcare names like ResMed or scanning for opportunities across other sectors, this curated view offers a streamlined entry point into AI-assisted trading.

2026 Outlook and What Investors Should Watch

The upcoming fiscal fourth-quarter 2026 earnings report on August 6 represents the most immediate catalyst for RMD shares. Consensus expectations call for revenue of roughly $1.46 billion and EPS of $2.90, with investors closely monitoring margin trends, mask and accessory resupply rates, and any updated commentary on the GLP-1 dynamic. Beyond the earnings print, the closing of the MatrixCare transaction in the first quarter of fiscal 2027 will be a key milestone, as will the pace of share repurchases funded by the $490 million in proceeds.

Longer term, ResMed's 2030 strategy centers on scaling its connected home-based care ecosystem, expanding AI-powered digital health capabilities, and broadening its addressable market beyond sleep apnea — as demonstrated by the Noctrix acquisition. The global home healthcare market is projected to grow at a compound annual rate of roughly 10.5% through 2033, providing a favorable secular tailwind. Key risks to monitor include competitive device launches, potential GLP-1 adoption acceleration, regulatory changes in reimbursement, and any escalation of global trade tensions that could affect the company's international supply chain and manufacturing footprint.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations